CM-272

Overview

CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a , DNMT1 , DNMT3A , DNMT3B and GLP with IC 50 s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis , inducing IFN-stimulated genes and immunogenic cell death.

Application

Products | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > DNA Methyltransferase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-101925
• CAS No.: 1846570-31-7
• Molecular Formula: C28H38N4O3
• Molecular Weight: 478.63
• Purity: 99.55%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.35 mM); Clear solution
• Availability: In-stock

Source

Original product source